Peptide Research Library
Explore peptide research, compound comparisons and clinical trial data. Browse guides to laboratory handling, COA verification and approval status, alongside UAE and GCC research context.
Comparisons and evidence trackers
GLOW vs KLOW vs Wolverine: What's in Each Peptide Blend
GLOW, KLOW and Wolverine compared: components as commonly listed, what KPV adds, the one combination study, blue GHK-Cu chemistry and blend COAs. Remy does not sell KLOW.
Orforglipron Phase 3 evidence
ATTAIN obesity and ACHIEVE type-2-diabetes Phase 3 results (peer-reviewed and sponsor topline), trial records, and the US obesity approval.
Survodutide Phase 3 evidence
SYNCHRONIZE obesity and MASLD Phase 3 results, peer-reviewed Phase 2 MASH and obesity data, and the completed cardiovascular-safety trial with results unpublished.
VK2735 Phase 2/3 evidence
Peer-reviewed subcutaneous VENTURE Phase 2, the oral VENTURE topline, the maintenance study, the pending VANQUISH Phase 3 program and the oral SUNRISE 1 and 2 Phase 3 trials registered on 9 October 2026 — subcutaneous and oral kept separate.
Browse by topic
Six starting points: retatrutide, individual compounds, GLP-1 science, trials and approval status, batch verification, and UAE and GCC guides. The full directory below lists every article.
Retatrutide Research Hub
The triple-agonist cluster: mechanism profiles, TRIUMPH trial data, dosing references, device guides, and approval status in one place.
GLP-1 and GIP Mechanism of Action
The receptor-by-receptor science of incretin agonism, plus the effect deep-dives that branch off it: muscle, bone, brain reward, discontinuation, and more.
Clinical trials & approval trackers
Approval-status pages, master trackers, trial timelines, and current filing context for obesity-pipeline compounds.
Research directory
Every research article on Remy Research, grouped by topic. Search above, or narrow the list by compound, evidence type or region.
Retatrutide (14)
Deep-dive retatrutide research coverage: triple-agonist mechanism, TRIUMPH trial data, pen hardware, safety signals, half-life, COA proof, and supplier checklists.
Is Retatrutide a GLP-3? GLP-3 Names Explained
Only as a nickname. The 1/2/3 myth, a decoder for GLP-3 RT, NL-3 RT and GLP-2 TZ, TRIUMPH-1 results and how to check a vial.
Is Retatrutide a Peptide or a Biologic? The 40-Amino-Acid Rule
FDA counts 40 alpha amino acids, Lilly counts 41: the protein rule, the 2025 ruling, the Seventh Circuit appeal and what the classification changes.
Retatrutide + Cagrilintide: What the Research Shows
One 2026 rat study, no human trials and the CagriSema precedent: the evidence ladder, blends vs separate vials, and cagrilintide vs eloralintide.
Retatrutide Dosage Guide: Phase 3 Titration Protocol
Retatrutide dosage calculator plus titration schedule: 2mg start, 4mg/9mg/12mg maintenance, pen click conversion, and dose-hold rules from the TRIUMPH trials.
Retatrutide Dubai Pricing: AED Pens & Vials
AED prices by strength and format, per-mg costs, pack pricing, pen vs vial value, cold-chain delivery and UAE regulatory status.
Retatrutide Half-Life: Why Once-Weekly Dosing Works
Retatrutide half-life is about 6 days in published Lilly research. See the PK data, why once-weekly dosing works, and how long washout may take.
TRANSCEND-T2D-1 Results: Retatrutide in Type 2 Diabetes
The first peer-reviewed reta Phase 3: HbA1c down up to 1.94 points and bodyweight up to 15.3% at 40 weeks in 537 adults with type 2 diabetes. The Lancet data, explained.
Retatrutide Side Effects: What the Clinical Trial Data Shows
Adverse-event data by dose from the phase 2 obesity and diabetes trials, the MASLD substudy, and phase 3 TRIUMPH — GI events, heart rate, dysesthesia, and the liver-fat facts behind the headlines.
Retatrutide Pen Specifications, Storage & Research Handling
Composition, storage, batch proof and documentation-led laboratory handling for the 30mg pen, without administration or personal-use instructions.
Retatrutide — Triple Agonist GLP-1/GIP/Glucagon Profile
Eli Lilly's triple agonist for GLP-1, GIP, and glucagon receptors. Phase 3 TRIUMPH data, mechanism, and positioning vs tirzepatide and CagriSema.
Retatrutide Side Effects: GI Rates, Safety Signals & Clinical Comparison
Dose-by-dose nausea, diarrhea, and vomiting rates from retatrutide Phase 2 (NEJM 2023) and TRIUMPH Phase 3 trials. Discontinuation data and GLP-1 comparisons.
Reta Peptide
What reta and reta peptide mean, how retatrutide works, what it does in research studies, and how COA evidence fits.
Retatrutide Phase 3 evidence
Peer-reviewed TRANSCEND-T2D-1, TRIUMPH-1 (NEJM) and TRIUMPH-2 (The Lancet) findings, TRIUMPH-3 sponsor topline results, trial records, and publication status.
Retatrutide Research Hub
The triple-agonist cluster: mechanism profiles, TRIUMPH trial data, dosing references, device guides, and approval status in one place.
Compound Profiles & Research (55)
Mechanism profiles and research data for individual compounds across the peptide and GLP-1 landscape, plus Dubai research-vial guides that link each peptide to its product page and batch-report status.
AICAR vs MOTS-c: AMPK Activators Compared
AICAR and MOTS-c both activate AMPK by different routes: mechanisms, animal and human evidence, side effects, FDA and WADA status.
Aleniglipron: Oral GLP-1 Trials & Phase 3
Published ACCESS findings, the Nature Medicine correction and the recruiting ACCOMPLISH phase 3 trials.
AOD 9604 Benefits, Side Effects and Trial Evidence
AOD-9604: rodent fat-metabolism data, the failed 24-week human trial, FDA-recorded side effects and its link to hGH 176-191.
AOD-9604 Dubai & UAE: Research Vial Guide
AOD-9604 Dubai guide — what the obesity trials found, FDA, UAE and WADA status, and batch-report checks. Research use only.
AOD-9604 UAE: Mechanisms, Forms and Research Use
Mechanism, six human trials, vial vs pen formats, AED prices, lab handling and FDA/WADA status.
Does Bacteriostatic Water Need to Be Refrigerated?
What the US label says about storage at 20 to 25°C, shelf life unopened and opened, and the benzyl alcohol neonate warning.
BPC 157 UAE: 10mg Research, Quality and Buying Guide
What the 10mg vial is, what the preclinical evidence shows, the COA and HPLC checks to ask for, storage, AED pricing and cold-chain delivery across the UAE.
BPC-157 Benefits and Side Effects: What Studies Show
BPC-157 benefits in animal models, the five small human studies, FDA’s 2026 safety findings and adverse-event reports, and WADA status.
Cerebrolysin Benefits and Side Effects: Trial Evidence
Dementia, stroke and brain injury trials, Cochrane reviews, side effects and FDA and EMA status for Cerebrolysin.
CJC-1295 + Ipamorelin Side Effects and Benefits
What human studies of CJC-1295 and ipamorelin show, FDA’s safety findings and 2024 advisory vote, and why the pair has never been tested.
Does CJC-1295 + Ipamorelin Work? UAE Guide
Published GH and IGF-1 data, DAC vs no-DAC half-life, sermorelin and tesamorelin compared, FDA and WADA status, lab storage and AED prices.
Dihexa Benefits and Side Effects: What Research Shows
Animal data on memory and brain injury, the retracted HGF/c-Met paper, absent human and safety data, regulatory status, and dihexa vs Semax.
Dihexa Research: Evidence Review
Dihexa evidence: angiotensin IV-derived peptidomimetic, the retracted mechanism paper, mixed independent animal data, no human data, and the fosgonimeton trials.
DSIP Peptide Benefits and Side Effects: What Studies Show
DSIP sleep claims against the evidence: rabbit and rat studies, small insomnia trials, reported side effects, the 2026 FDA vote and WADA status.
DSIP Research: Sleep Peptide Evidence
DSIP (emideltide) evidence: 1977 Basel discovery, missing gene and receptor, positive versus null sleep trials, safety gaps, and the July 2026 FDA vote.
Epitalon Benefits and Side Effects: What Studies Show
Epitalon telomere and aging claims against the evidence: cell studies, mixed mouse results, one dominant research group, FDA’s safety findings and the 2026 vote.
Epitalon (Epithalon) Research Evidence
Epitalon (AEDG) evidence: Epithalamin origin, cell-culture telomerase data, mixed rodent lifespan results, 2026 FDA status, and how concentrated the research base is.
FOXO4-DRI Research: Senolytic Peptide Data & Mechanism
FOXO4-DRI senolytic peptide research: FOXO4-p53 disruption, D-retro-inverso stability, senescent cell clearance, and dasatinib+quercetin comparison.
GHK-Cu Side Effects and Benefits: What Studies Show
GHK-Cu side effects and benefits from topical trials and lab studies, topical vs injectable research formats, FDA compounding status and AHK-Cu.
GHK-Cu Peptide: Research Guide for UAE Labs
Copper tripeptide chemistry, gene-expression data, skin, hair and wound models, storage, FDA status and UAE sourcing.
GLOW Peptide Pen: Benefits, Side Effects and What Studies Show
No study has tested the blend in the GLOW peptide pen. What GHK-Cu, BPC-157 and TB-500 each show, the one combination study, FDA safety findings and WADA status.
HGH Fragment 176-191: Research, Mechanism, Benefits and Risks
Structure, proposed lipolytic mechanism, rodent and AOD-9604 trial evidence, comparisons and WADA/UAE status.
IGF-1 LR3 Side Effects and Benefits: Research Data
IGF-1 LR3: what cell and rat studies found, why no human trials exist, and the IGF-1 class warnings on the mecasermin label.
Ipamorelin Side Effects and Benefits: What Studies Show
What animal and human studies show for ipamorelin, why its surgical trial failed, FDA’s Category 2 safety concerns and WADA status.
Kisspeptin-10 Benefits and Side Effects: What Human Studies Show
Kisspeptin-10 and LH, FSH and testosterone in human studies, why women respond differently, kisspeptin-54 trials, FDA Category 2 and WADA status.
KPV Peptide Benefits and Side Effects: What Studies Show
KPV benefits in mouse colitis and cell studies, why no human data exist, FDA’s 2026 finding that human safety is unknown, and WADA status.
KPV Peptide in the UAE: Research, Formats and Buying Guide
What KPV is, what the gut and skin research shows, how it compares with BPC-157 and GHK-Cu, the COA checks to ask for, and cold-chain delivery across the UAE.
Maridebart Cafraglutide (MariTide) Profile
Amgen’s antibody–peptide conjugate that blocks GIPR and activates GLP-1R: structure, Phase 2 data, MARITIME Phase 3 status (no results yet) and how it compares with retatrutide and tirzepatide.
Melanotan 1 vs 2: Afamelanotide, Melanotan II and Side Effects
Afamelanotide (Scenesse) vs Melanotan II: receptors, human studies, case-report side effects and where each stands with FDA, EMA and WADA.
MOTS-c Benefits and Side Effects: What Studies Show
MOTS-c benefits in mouse and cell studies, what human level studies show, FDA’s 2026 finding of no human safety data, and WADA status.
NAD+ Benefits and Side Effects: What Studies Show
NAD+: what precursor trials found, how IV and oral study formats compare, infusion side effects and FDA endotoxin alerts.
NAD+ Research: Coenzyme Biology and Evidence Review
NAD+ evidence: coenzyme chemistry, age-related decline by tissue, thin direct human data versus NR/NMN trials, FDA safety alerts, and 2026 status.
Orforglipron — Oral Non-Peptide GLP-1 Profile
Eli Lilly's oral non-peptide GLP-1 agonist, FDA-approved as Foundayo. Mechanism, ACHIEVE and ATTAIN trial data, and positioning vs injectable GLP-1s.
Oxytocin Side Effects and Research Benefits: What Studies Show
Oxytocin side effects from the approved label, water intoxication, and what the bonding, trust, autism and obesity studies actually found.
Oxytocin Peptide Research: Nonapeptide Hormone Evidence Review
Oxytocin evidence: cyclic nonapeptide chemistry, the approved childbirth use, trust and autism results that did not hold up in larger studies, obesity data, and 2026 status.
PT-141 Side Effects and Benefits: What Bremelanotide Trials Show
PT-141 side effects from the Vyleesi label (nausea, flushing, blood pressure, skin darkening), the HSDD trial results and the early studies in men.
Selank Side Effects and Benefits: What Studies Show
Label safety data, withdrawal and dependence evidence, small anxiety trials, FDA status and the gaps in the Selank evidence.
Selank Research: Tuftsin Analog Evidence
Selank evidence: tuftsin-analog chemistry, Russian OTC registration, rodent enkephalinase and GABA data, small benzodiazepine-comparator trials, and 2026 status.
Semaglutide — GLP-1 Receptor Agonist Profile
Novo Nordisk's GLP-1 receptor agonist. Mechanism, STEP and SUSTAIN Phase 3 data, Ozempic/Wegovy/Rybelsus differences, and next-gen positioning.
Semax Benefits and Side Effects: What Studies Show
BDNF and learning data in rats, small Russian stroke studies, label side effects, FDA status and the gaps in the Semax evidence.
Semax Research: ACTH(4-10) Analog Evidence
Semax evidence: ACTH(4-10) analog chemistry, Russian registration, rat BDNF and stroke-model data, small Russian human studies, and 2026 FDA status.
SLU-PP-332 Side Effects and Benefits: Preclinical Data
SLU-PP-332 is preclinical only: mouse and cell benefits, why human side effects are unknown, developer-flagged limits, and WADA’s 2027 listing.
SLU-PP-332 Research: ERR Agonist Evidence Review
SLU-PP-332 evidence: a small-molecule ERR agonist, not a peptide. Mouse endurance and metabolic data, no human data, known limitations, and the 2027 WADA listing.
SS-31 Peptide Benefits, Side Effects and FDA Approval
SS-31 (elamipretide): the 2025 Forzinity approval for Barth syndrome, what its trials found, and the FDA label’s side-effect data.
TB-500 Benefits and Side Effects: What Studies Show
TB-500 benefits in animal studies, why most data concern full thymosin beta-4, FDA’s 2026 safety findings, compounding vote and WADA status.
Tesamorelin Research: GHRH Analog Data and Clinical Limits
GHRH analog biology, HIV lipodystrophy trial data, liver-fat findings in HIV-associated NAFLD, and the label limits researchers need to keep in view.
Tesamorelin vs Sermorelin: GHRH Analogs Compared
Structure, FDA status, visceral fat and growth trials, side effects and WADA status for tesamorelin and sermorelin, plus where ipamorelin fits.
Thymosin Alpha 1 Benefits and Side Effects: Research Data
Thymosin alpha-1 immune claims against the evidence: mixed hepatitis trials, the null TESTS sepsis trial, side effects, approvals and FDA status.
Thymosin Alpha-1 (Thymalfasin) Research
Thymosin alpha-1 evidence: prothymosin origin, TLR immune data, null sepsis and hepatitis trials, approvals in China and Italy, and the 2024 FDA vote.
VIP Peptide Benefits and Side Effects: What Studies Show
VIP claims against the evidence: mouse inflammation studies, small lung studies, two failed US aviptadil trials, side effects and regulatory status.
VIP (Vasoactive Intestinal Peptide) Research: Evidence Review
VIP evidence: VPAC receptors, VIPoma, small lung studies, two US aviptadil COVID-19 trials that missed their endpoints, and 2026 FDA, EMA and WADA status.
BPC-157 Dubai: Research Vial & COA Guide
BPC-157 Dubai guide — clinic vs vial vs capsules, evidence by type, FDA, UAE and WADA status, and batch-report checks. Research use only.
MOTS-c Dubai: Research Vial, Evidence and COA Guide
MOTS-c Dubai guide — mouse and human evidence sorted by type, FDA, UAE and WADA status, and batch-report checks. Research use only.
Tesamorelin Dubai: Egrifta vs Research Vial
Tesamorelin Dubai guide — Egrifta’s narrow FDA approval vs research vials, UAE and WADA status, label safety and batch-report checks. Research use only.
Brenipatide — GIP/GLP-1 Dual Agonist Profile
Dual GIP / GLP-1 agonist (LY-3537031) in Eli Lilly’s Phase 2/3 RENEW programme for addiction and mood.
GLP-1 & Incretin Science (11)
The receptor-level science behind GLP-1, GIP and glucagon agonism, and the effect-specific deep dives that branch off the mechanism pillar: body composition, bone, brain reward, discontinuation, and more.
Exenatide-Related Peptide Energy Landscapes
An August 2026 methods preprint uses a simplified residue model to explore energy distributions in two small protein systems.
GLP-1 Ramadan UAE 2027: Fasting Research
Gulf semaglutide evidence, the T-RAM trial and retatrutide unknowns, with Ramadan FAQs.
GLP-1 Blood Sugar vs Weight Loss: A Mediation Study
A July 2026 preprint uses records from ten hospitals to separate a BMI-mediated pathway from other pathways in an estimated glucose-lowering effect.
GLP-1 Digital Twins: Prediction and Uncertainty
An October 2026 simulation study examines why models that fit the same observations can disagree about a different treatment strategy.
GLP-1 and GIP: Mechanism of Action Explained
Receptor-by-receptor mechanism of action: what GLP-1, GIP, and glucagon agonism each drive, where side effects trace back, and what clinical trials measure.
What Happens When You Stop GLP-1 Medications?
Weight regain data after stopping GLP-1s. Semaglutide, tirzepatide & liraglutide discontinuation studies with timelines and trial results.
Missing Data in GLP-1 Research: Can AI Help?
A May 2026 preprint tests a method for drawing treatment-effect estimates from incomplete clinical records, then applies it to Swiss primary care.
GLP-1 & Muscle Loss — Composition Data (2026)
Lean-mass and body-composition data from semaglutide, tirzepatide, and retatrutide trials — what the DEXA and lean-mass endpoints show.
GLP-1 Receptor Potency: Quantum-Inspired Prediction
An October 2026 study reports modest prediction gains and a classical control that helps explain where those gains may come from.
Which Obesity Drugs Actually Matter for Sleep Apnea?
Zepbound is the only obesity drug FDA-approved for sleep apnea. Retatrutide OSA data from the TRIUMPH programme; MariTide in Phase 3 OSA trials. Trial data, AHI reduction & pipeline.
Supplements to Take While on GLP-1s
Which supplements do people take on GLP-1s? Compare protein, fiber, electrolytes, vitamins and creatine using community reports and clinical evidence.
Clinical Trials & Approval Status (15)
FDA, EMA and NDA status pages, plus Phase 3 evidence trackers, pipeline timelines and trial readouts.
Foundayo (Orforglipron) Deep Dive 2026 | Pricing & Impact
Secondary Foundayo deep dive covering pricing, label context, oral GLP-1 positioning, and market impact after approval. Use the status page for approval.
Is CagriSema FDA Approved? No — Status 2026
CagriSema FDA approval tracker: Novo Nordisk NDA, REDEFINE and REIMAGINE Phase 3 data, FDA decision expected Q4 2026. Updated October 2026.
Is Orforglipron Approved? Yes, Approved as Foundayo
Yes. Orforglipron was FDA approved on April 1, 2026 as Foundayo. Start here for the direct status answer, then open the deeper market-impact page.
Is Retatrutide FDA Approved in 2026?
Retatrutide's FDA status as of October 2026: five positive Phase 3 TRIUMPH readouts, not approved, US filing planned by Q1 2027.
Survodutide FDA Approval Status 2026: Not Approved, Not Filed
Survodutide is not FDA approved as of October 2026. SYNCHRONIZE-1 and -2 results, LIVERAGE MASH trials, and no filing announced yet.
Obesity Drug Approval Tracker 2026: Status Hub, NDAs & Pipeline
Live 2026 tracker of every obesity drug: FDA approvals, NDA filings, Phase 3 readouts. Retatrutide, CagriSema, orforglipron, survodutide — status at a glance.
Obesity Drug Pipeline Timeline 2026
2026 obesity-drug pipeline calendar with filing dates, Phase 3 readouts, FDA decision windows, launch timing, and major catalysts across key programs.
Retatrutide TRIUMPH Trial Tracker
Track retatrutide TRIUMPH milestones, readout timing, safety signals, and how the data feeds Lilly's planned US filing by Q1 2027. Use the status page for approval.
Zenagamtide (Amycretin): Phase 3 Status & FDA Tracker
Zenagamtide (amycretin) latest research update: up to 14.6% weight loss at 36 weeks in type 2 diabetes (Phase 2), GLP-1/amylin mechanism, and Phase 3 status.
Approval Trackers
Approval-status pages, master trackers, trial timelines, and current filing context for obesity-pipeline compounds.
CagriSema Phase 3 evidence
REDEFINE and REIMAGINE Phase 3 results — including the REDEFINE 4 miss versus tirzepatide — with trial records and publication status.
Orforglipron Phase 3 evidence
ATTAIN obesity and ACHIEVE type-2-diabetes Phase 3 results (peer-reviewed and sponsor topline), trial records, and the US obesity approval.
Survodutide Phase 3 evidence
SYNCHRONIZE obesity and MASLD Phase 3 results, peer-reviewed Phase 2 MASH and obesity data, and the completed cardiovascular-safety trial with results unpublished.
VK2735 Phase 2/3 evidence
Peer-reviewed subcutaneous VENTURE Phase 2, the oral VENTURE topline, the maintenance study, the pending VANQUISH Phase 3 program and the oral SUNRISE 1 and 2 Phase 3 trials registered on 9 October 2026 — subcutaneous and oral kept separate.
Compounded GLP-1s in 2026
Post-shortage state of US semaglutide and tirzepatide compounding: wind-down deadlines, the April 2026 FDA 503B proposal, enforcement actions, adverse-event data, and where retatrutide sits.
Comparisons (14)
Head-to-head data tables and format guides comparing molecules, vial workflows, dosing schedules, and tolerability profiles.
Best Obesity Drug in 2026: 8-Drug Decision Guide
Decision guide comparing 8 obesity drugs by efficacy, route, tolerability, and approval stage, with verdicts for approved, pipeline, and oral options.
CagriSema vs Tirzepatide — REDEFINE 4 Results
REDEFINE 4 head-to-head: CagriSema 20.2% vs tirzepatide 23.6% weight loss at 84 weeks. Full data breakdown and mechanism comparison.
GHRH Peptides Compared — Tesamorelin, CJC-1295, Sermorelin, Ipamorelin
GHRH-analog vs GHRP across four compounds: structure, half-life, albumin binding, and where the preclinical literature stops short.
GLOW vs KLOW vs Wolverine: What's in Each Peptide Blend
GLOW, KLOW and Wolverine compared: components as commonly listed, what KPV adds, the one combination study, blue GHK-Cu chemistry and blend COAs. Remy does not sell KLOW.
Oral GLP-1 for Weight Loss in 2026: Wegovy Pill vs Foundayo vs VK2735
Oral GLP-1 options for weight loss in 2026: how the Wegovy pill, Foundayo (orforglipron), and VK2735 compare on efficacy, dosing, and approval status.
Orforglipron vs Tirzepatide: 2026 Trial Data
No head-to-head trial: ATTAIN vs SURMOUNT weight data by estimand, label side effects, ATTAIN-MAINTAIN and why one is a pill and the other a peptide injection.
Peptide Pens vs Vials: Stability, Cost per mg and COAs
Lyophilized vials, kits, pre-filled and dual-chamber pens compared on stability, heat in transit, losses, cost per usable mg and filled-pen COAs.
Are Peptides Steroids?
No. Peptides and steroids are different chemical classes. Compare their structures, hormone roles and how SARMs fit into the terminology.
Foundayo vs Wegovy Pill — 2026 Head-to-Head Data
Foundayo (orforglipron) vs Wegovy pill (oral semaglutide 25 mg): cross-trial efficacy, ACHIEVE-3 head-to-head, dosing windows, and US/UK/UAE access.
Ozempic vs Mounjaro vs Wegovy: Side Effects Compared (2026 Data)
Ozempic, Mounjaro & Wegovy side effects compared from trial data. Nausea, GI effects, injection-site reactions & adverse event frequencies.
Retatrutide vs Semaglutide vs Tirzepatide: Dosage Comparison
Side-by-side dosage comparison of retatrutide, semaglutide, and tirzepatide — titration schedules, dose ranges, and Phase 3 clinical outcomes.
Semax vs Selank: Research Comparison
Semax vs Selank compared: sequences, the three studies that tested both peptides, and why none shows that one is better overall.
Saxenda vs Ozempic (Wegovy)
Semaglutide 2.4 mg (the Wegovy dose) gave 15.8% vs 6.4% for Saxenda in STEP 8 (about 2.5x). Side-by-side dosing, cost, side effects & which one researchers recommend.
Zenagamtide (Amycretin) vs CagriSema: Single Molecule vs Fixed-Dose Combination
Zenagamtide (single molecule) vs CagriSema (fixed-dose combo): both target GLP-1/amylin but differ structurally. Mechanism, data & pipeline.
Protocols, Safety & Tools (15)
Reconstitution, storage, mixing, sourcing, legality, blend rationale, body-composition impact and adverse-event references, plus the pen planning tools and the batch-report library.
How to Reconstitute Peptides with Bacteriostatic Water
How to reconstitute peptides with bacteriostatic water: step-by-step mixing, concentration math, sterile handling, storage rules, and research-use guidance.
BPC-157 Storage & Stability
How to store BPC-157 10mg vials: listed temperature, light and moisture, powder vs solution, what the sequence suggests and arrival checks.
Are Peptides Legal? Global Overview
Research-use status across the US, UAE, UK, EU, Canada, Australia, and other markets, with clear boundaries for personal-use and pharmacy-style claims.
Janoshik vs Finnrick vs Freedom Diagnostics
Two testing labs and a ratings platform compared: methods, who sends the sample, how reports are verified, stated prices, accreditation claims and what one COA cannot prove.
Peptide User Survey 2026: Seller-Run Poll Data
Self-selected survey run by a US peptide seller: RUO sourcing, annual spend, and the limits of online-market evidence.
What Not to Mix with Peptides
What not to mix with peptides: reconstitution compatibility, peptide-peptide mixing rules, supplement interactions, medication overlap, and storage conflicts.
Peptide supplier checklist
A printable record for the product, lab report, report details, delivery terms and questions to settle before ordering.
Peptide COA field reference
Read the fields on a published retatrutide report, identify the submitted sample and keep a record of what each test covers.
Peptide delivery receiving checklist
Record arrival time, labels, seals, measured temperature and any damage before contacting support about a delivery.
How to Store Peptides
How to store lyophilized peptides, reconstituted solutions and pre-filled pens: temperatures, shelf life and a receiving checklist for warm parcels.
HCG (Human Chorionic Gonadotropin): Reference Standards & 2026 Supply Status
HCG reference: heterodimeric glycoprotein structure, APHRODITE criteria (Andrology 2026), post-androgen spermatogenesis recovery, and the six-year BPCIA-driven U.S. shortage.
Retatrutide Pen Planner
Retatrutide pen planning for 10mg, 20mg, 30mg and 40mg pens: enter an amount in mg, how often and for how many weeks to see the clicks per amount and the number of pens needed.
Retatrutide Pen Clicks to mg
Format-specific clicks-to-mg chart and converter for the 10mg, 20mg, 30mg and 40mg 300-click pens, with batch COA links and no clinical dose conversion.
COA Library
Janoshik HPLC reports and batch records for every published batch; each product page shows its own testing status.
Data and Citation: Trackers, CSVs and Datasets
Remy Research trackers, CSV downloads and the COA batch dataset in one place, with last-updated dates, a citation format and reuse terms.
UAE, GCC & Lebanon Guides (11)
Country and emirate-level research coverage — Dubai, Abu Dhabi, KSA, Qatar, Lebanon, and UAE-wide market context.
Are Peptides Legal in Dubai?
See what UAE medicine and customs rules cover, where research-use peptide listings fit, and how to verify a supplier in Dubai.
Controlled Medicines Permits for the UAE: Practical Guide for Researchers, Travelers, and Labs
Who needs a controlled medicines permit, how to apply, the documents and quantity limits, and why research peptides sit outside the personal-use permit system.
Peptides for Hair Loss: AHK-Cu vs GHK-Cu vs PTD-DBM
AHK-Cu follicle data, the copper-free ALAVAX trial, and PTD-DBM pathway research, with human-evidence limits.
UAE Obesity Rate: 2026 Statistics & the GLP-1 Landscape
The UAE obesity rate is 22.4% of adults in the 2024–25 national survey. WHO’s estimate, Dubai figures, diabetes rates and the UAE GLP-1 market.
Research Peptides in the UAE
Research peptides in the UAE with supplier verification steps, COA proof, delivery context, and current public product availability for Dubai researchers.
Retatrutide Clinical Trials UAE
No UAE-listed sites appeared in the registrational retatrutide study records reviewed for this page. See trial status, data, and site verification.
Retatrutide 30mg Pen Dubai
The 300-click flagship retatrutide pen, with a published Janoshik batch report (RETP002, 99.262% HPLC) and same-day Dubai delivery for orders before 4 PM.
Retatrutide 20mg Pen Dubai
20mg pen guide with 200-click math, Janoshik pen batch RET-20-C-2604-001, 99.841% HPLC purity, and tiered AED pricing.
Retatrutide 40mg Vial Dubai
40mg lyophilised vial guide covering reconstitution workflow, cost per mg, cold-chain dispatch, and when labs choose vial over pen.
Retatrutide in Abu Dhabi
Abu Dhabi research-use guide: six batch-documented formats (of 18 listed), flagship 30mg pen COA proof, AED price tiers, and prepaid tracked cold-chain delivery to the capital: next day for orders before 12 PM (noon), otherwise within two days.
Retatrutide UAE: formats, prices and ordering
Every retatrutide pen, vial and kit Remy Research lists, with AED prices, stock and batch evidence status.